Bristol -Myers Squibb News

InterMune Announces Appointments of Senior Leadership to Prepare for Potential Launch of Pirfenidone

Widespread Generic Erosion of Atypical Antipsychotics Will Cause the Bipolar Disorder Drug Market to Decline By More Than $1 Billion Through 2018

Repligen Reports Second Quarter Fiscal Year 2010 Financial Results

Reuters - 2 hours ago
WALTHAM, Mass., Nov. 5 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for ...

Widespread Generic Erosion of Atypical Antipsychotics Will Cause the Bipolar Disorder Drug Market to Decline By More Than $1 Billion Through 2018

Repligen Reports Second Quarter Fiscal Year 2010 Financial Results

PharmaLive.com - 15 minutes ago
WALTHAM, MA – November 5, 2009 – Repligen Corporation (NASDAQ: RGEN) today reported results for the second quarter of fiscal year 2010, ended September 30, 2009. Total revenue for the quarter was ...

A Cure for Cancer?

CNBC - Nov 3, 2009
Bristol-Myers Squibb and Pfizer are “the most conservative ways to play the war against cancer,” Cramer said Monday. Both companies own strong drug pipelines, the stocks are cheap, and the share ...

Zyngenia, Inc. Raises $10 Million in Series A Funding

Reuters - 1 hour ago
- Next-Generation Biotherapeutics Company Appoints Board of Directors, Management Team - ROCKVILLE, Md., Nov. 4 /PRNewswire/ -- Zyngenia, Inc., a privately held biotherapeutics company focused on ...

Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference

Bristol-Myers Squibb on Baraclude: Better efficacy than competitor

A Cure for Cancer?

CNBC - 10 hours ago
Bristol-Myers Squibb and Pfizer are “the most conservative ways to play the war against cancer,” Cramer said Monday. Both companies own strong drug pipelines, the stocks are cheap, and the share ...